Comparing SeaStar Medical (ICU) & Its Competitors

SeaStar Medical (NASDAQ:ICU) is one of 454 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare SeaStar Medical to similar companies based on the strength of its institutional ownership, valuation, profitability, risk, dividends, analyst recommendations and earnings.

Profitability

This table compares SeaStar Medical and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	N/A	N/A	-741.57%
SeaStar Medical Competitors	-8,301.93%	-131.62%	-25.63%

Volatility & Risk

SeaStar Medical has a beta of -1.18, indicating that its share price is 218% less volatile than the S&P 500. Comparatively, SeaStar Medical’s peers have a beta of 1.18, indicating that their average share price is 18% more volatile than the S&P 500.

Valuation and Earnings

This table compares SeaStar Medical and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SeaStar Medical	N/A	-$26.23 million	-0.36
SeaStar Medical Competitors	$214.36 million	$13.74 million	-69.85

SeaStar Medical’s peers have higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 30.5% of shares of all “Biotechnology” companies are owned by institutional investors. 4.5% of SeaStar Medical shares are owned by insiders. Comparatively, 21.3% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for SeaStar Medical and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	0	0	0	0	N/A
SeaStar Medical Competitors	667	2445	6355	97	2.62

As a group, “Biotechnology” companies have a potential upside of 108.97%. Given SeaStar Medical’s peers higher probable upside, analysts clearly believe SeaStar Medical has less favorable growth aspects than its peers.

Summary

SeaStar Medical peers beat SeaStar Medical on 7 of the 10 factors compared.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.